Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Trial of Lintuzumab Ac-225 in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations

Trial Profile

Phase 2 Trial of Lintuzumab Ac-225 in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Lintuzumab Ac-225 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 14 Mar 2018 According to an Actinium Pharmaceuticals media release, Dr. Jehan Rowlands will be responsible for supporting the development of a regulatory pathway for this planned trial.
    • 28 Feb 2018 According to an Actinium Pharmaceuticals media release, this trial will be conducted with the MDS Clinical Research Consortium.
    • 20 Feb 2018 According to an Actinium Pharmaceuticals media release, company will discuss about this study at the the BMT Tandem Meetings, the combined annual meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top